Robert MD - Novavax Senior Officer
| NVAX Stock | USD 8.72 0.10 1.16% |
Executive
Robert MD is Senior Officer of Novavax
| Address | 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 |
| Phone | 240 268 2000 |
| Web | https://www.novavax.com |
Novavax Management Efficiency
The company has return on total asset (ROA) of (0.1076) % which means that it has lost $0.1076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.982) %, meaning that it created substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.30 in 2024, whereas Return On Tangible Assets are likely to drop (0.34) in 2024. At this time, Novavax's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 747 M in 2024, whereas Intangible Assets are likely to drop slightly above 4.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shannon JD | Moderna | 53 | |
| Sean Marett | BioNTech SE | 59 | |
| Thomas Hong | Inovio Pharmaceuticals | N/A | |
| Adrian Kemp | AstraZeneca PLC ADR | N/A | |
| Michelle Hall | Moderna | N/A | |
| Lori Panther | Moderna | N/A | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| E MBA | Inovio Pharmaceuticals | N/A | |
| Charbel MPH | Moderna | N/A | |
| Sylke Maas | BioNTech SE | N/A | |
| Sebastian MD | BioNTech SE | N/A | |
| James Ryan | BioNTech SE | 49 | |
| Peter Kies | Inovio Pharmaceuticals | 61 | |
| Phil White | Moderna | N/A | |
| Melanie MBA | Moderna | N/A | |
| Colleen Hussey | Moderna | N/A | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Katalin Kariko | BioNTech SE | N/A | |
| Lisa Birringer | BioNTech SE | N/A | |
| Tracey Franklin | Moderna | 44 | |
| Jeffrey Skolnik | Inovio Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.11 |
Novavax Leadership Team
Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, President COO | ||
| Stanley Erck, CEO and President Director and Member of Fin. Committee | ||
| Mark Casey, Chief VP | ||
| JD Esq, Senior Officer | ||
| Robert MD, Senior Officer | ||
| Richard Crowley, Executive COO | ||
| Ian Watkins, Executive Officer | ||
| Elaine OHara, Executive Officer | ||
| John III, Chief VP | ||
| Biegie Lee, VP Officer | ||
| Gale Smith, VP Scientist | ||
| Silvia MBA, Executive Officer | ||
| Erika Trahan, Associate Relations | ||
| John MBA, CEO President | ||
| Gregory Glenn, Senior Vice President - Research & Development | ||
| Ruxandra MD, EVP Development | ||
| James CFA, CFO VP |
Novavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novavax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (1.54) % | ||||
| Current Valuation | 720.59 M | ||||
| Shares Outstanding | 160.18 M | ||||
| Shares Owned By Insiders | 4.37 % | ||||
| Shares Owned By Institutions | 60.11 % | ||||
| Number Of Shares Shorted | 41.51 M | ||||
| Price To Earning | (1.36) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.